Drug Profile
GSK 202405
Alternative Names: 202405Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 30 Nov 2004 Phase-II clinical trials in Chronic obstructive pulmonary disease (unspecified route)